Target type: biologicalprocess
The chemical reactions and pathways involving phosphatidic acid, any derivative of glycerol phosphate in which both the remaining hydroxyl groups of the glycerol moiety are esterified with fatty acids. [ISBN:0198506732]
Phosphatidic acid (PA) is a central intermediate in lipid metabolism, playing a crucial role in various cellular processes. Its metabolism is tightly regulated and involves a complex interplay of enzymes. The process begins with the synthesis of PA from diacylglycerol (DAG) by the enzyme diacylglycerol kinase (DGK). DGK isoforms are differentially expressed in various tissues and have distinct regulatory mechanisms.
PA can also be generated through the hydrolysis of phosphoinositides by phospholipases C and D, or by the dephosphorylation of phosphatidylinositol 4-phosphate (PIP) by phosphatidylinositol 4-phosphatase. These alternative pathways contribute to the dynamic regulation of PA levels in cells.
PA is a precursor for the synthesis of other important phospholipids, including phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylinositol (PI). Its conversion to these phospholipids is mediated by specific enzymes, such as CTP:phosphocholine cytidylyltransferase (CCT) and phosphatidylinositol synthase (PIS).
Beyond its role as a precursor for other lipids, PA itself exerts a range of cellular functions. It acts as a second messenger, modulating intracellular signaling pathways involved in cell growth, proliferation, and survival. PA activates various downstream signaling molecules, including protein kinase C (PKC), phosphoinositide 3-kinase (PI3K), and Ras.
PA also interacts with membrane proteins, influencing their activity and localization. For example, PA can bind to and activate certain ion channels, regulate the trafficking of proteins, and contribute to membrane organization.
In addition to its involvement in cellular signaling, PA plays a role in the formation of lipid droplets, which are organelles responsible for storing neutral lipids. PA can also be incorporated into the lipid bilayer, modulating membrane fluidity and curvature.
The metabolic fate of PA is determined by its conversion to other lipids or its degradation. PA can be dephosphorylated by lipid phosphatases, yielding DAG, or it can be converted to CDP-diacylglycerol (CDP-DAG), a precursor for the synthesis of cardiolipin and phosphatidylglycerol.
The metabolic process of phosphatidic acid is highly complex and tightly regulated, ensuring the proper balance of PA levels in cells. Dysregulation of PA metabolism has been implicated in various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. Understanding the intricate mechanisms governing PA metabolism is crucial for developing novel therapeutic strategies targeting these diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Group 3 secretory phospholipase A2 | A group 3 secretory phospholipase A2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9NZ20] | Homo sapiens (human) |
Phospholipase A2, membrane associated | A phospholipase A2, membrane associated that is encoded in the genome of human. [PRO:DNx, UniProtKB:P14555] | Homo sapiens (human) |
85/88 kDa calcium-independent phospholipase A2 | An 85/88 kDa calcium-independent phospholipase A2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O60733] | Homo sapiens (human) |
Group 10 secretory phospholipase A2 | A group 10 secretory phospholipase A2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O15496] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
quinacrine | quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9. Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2. | acridines; aromatic ether; organochlorine compound; tertiary amino compound | antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor |
nifedipine | Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. | C-nitro compound; dihydropyridine; methyl ester | calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent |
ubenimex | ubenimex: growth inhibitor | ||
5-benzyloxytryptophan | |||
fpl 67047xx | FPL 67047XX: inhibits phospholipase A2; structure in first source | ||
3-octylthio-1,1,1-trifluoro-2-propanone | 3-octylthio-1,1,1-trifluoro-2-propanone: a pesticide synergist; inhibits juvenile hormone esterase | ||
varespladib | aromatic ether; benzenes; dicarboxylic acid monoamide; indoles; monocarboxylic acid; primary carboxamide | anti-inflammatory drug; antidote; EC 3.1.1.4 (phospholipase A2) inhibitor | |
ly 311727 | LY 311727: a potent & selective inhibitor of human non-pancreatic secretory phospholipase A2; structure given in first source | ||
amentoflavone | biflavonoid; hydroxyflavone; ring assembly | angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite | |
ochnaflavone | ochnaflavone : A biflavonoid with an ether linkage between the B-rings of the apigenin and luteolin subunits. It has been isolated from several members of the Ochnaceae plant family. ochnaflavone: from Lonicera japonica; structure given in first source | aromatic ether; biflavonoid; hydroxyflavone | anti-inflammatory agent; antiatherogenic agent; antibacterial agent; EC 3.1.1.4 (phospholipase A2) inhibitor; leukotriene antagonist; plant metabolite |
manoalide | manoalide : A sesterterpenoid isolated from the marine sponge Luffariella variabilis and which has been shown to exhibit inhibitory activity towards phospholipase A2. manoalide: phospholipase A2 inhibitor; sesterterpene from marine sponge L. variabilis; structure given in first source | butenolide; lactol; sesterterpenoid | EC 3.1.1.4 (phospholipase A2) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; metabolite |
ym 26734 | YM 26734: inhibits group II phospholipase A2; structure given in first source | ||
indoxam | indoxam: structure in first source | ||
bolinaquinone | bolinaquinone: a marine sesquiterpenoid from sponge Dysidea sp. with anti-inflammatory activity; structure in first source | ||
cacospongionolide b | cacospongionolide B: isolated from the sponge Fasciospongia cavernosa; structure in first source |